Medicare Part D after 2 years

American Journal of Managed Care

Volumn 15, Issue 8, 2009, Pages 536-544

  Joyce, Geoffrey F ^a   Goldman, Dana P ^a   Vogt, William B ^a   Sun, Eric ^a,b   Jena, Anupam B ^a,b  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MARKET; MEDICARE; MONITORING; PRIORITY JOURNAL;

AGED; HEALTH EXPENDITURES; HUMANS; MEDICARE PART D; PHARMACEUTICAL SERVICES; PRESCRIPTION DRUGS; PROGRAM EVALUATION; UNITED STATES;

EID: 69749096423     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
2. Poisal JA. Reporting of drug expenditures in the MCBS. Health Care Financ Rev. 2003;25(2):23-36.
3. Rice T, Desmond K, for The Henry J. Kaiser Family Foundation. Low-Income Subsidies for the Medicare Prescription Drug Benefit: The Impact of the Asset Test. April 2005. Publication 7304. http://www.kff.org/medicare/7304.cfm. Accessed January 8, 2008.
4. Cubanski J, Neuman P. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood). 2007;26(1):w1-12.
5. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148(3):169-177. (Pubitemid 351665504)
6. Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007;26(6):1735-1744.
7. Winter J, Balza R, Caro F, et al. Medicare prescription drug coverage: consumer information and preferences. Proc Natl Acad Sci U S A. 2006;103(20):7929-7934.
8. Hsu J, Fung V, Price M, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299(16):1929-1936.
9. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication non-adherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299(16):1922-1928. (Pubitemid 351574922)
10. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359. (Pubitemid 43801280)
11. Joyce GF, Goldman DR Karaca-Mandic R Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
12. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini R Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655. (Pubitemid 24276866)
13. Hoadley J, for The Health Policy Institute, Georgetown University; Hargrave E, for NORC at the University of Chicago; and Cubanski J, Neuman T, for The Henry J. Kaiser Family Foundation. The Medicare Part D Coverage Gap: Costs and Consequences in 2007. August 2008. Publication 7811. http://www.kff.org/ medicare/7811.cfm. Accessed May 28, 2009.
14. Scott Morton FM. Prescription Drug Pricing and Negotiation: An Overview and Economic Perspectives for the Medicare Prescription Drug Benefit.Testimony for the Senate Finance Committee. January 11, 2007. http://finance.senate.gov/ hearings/testimony/2007test/011107fmtest.pdf. Accessed May 28, 2009.
15. Congressional Budget Office. A Detailed Description of CBO's Cost Estimate for the Medicare Prescription Drug Benefit. July 2004. http://www.cbo.gov/doc.cfm?index=5668&type=0. Accessed May 28, 2009.